reports
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Biddi...
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures Bids due on December 2, 2019 by 5:00 p.m. Eastern Time WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order approving Sienna’s proposed bidding procedures and Chapter 11 sale process timeline (the “Bidding Procedures Order”).1 Under the Bidding Procedures...
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delist...
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice -- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 12, 2019, the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on the Nasdaq Stock Market (“Nasdaq”), subject to certain conditions, including the following: On or be...
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001...
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair WESTLAKE VILLAGE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a Premarket Notification 510(k) submission to the U.S. Food and Drug Administration (FDA) for SNA-001, a topical pre-treatment to standard laser devices to remove unwanted light hair, and has received acknowledgement from FDA that the submission has been accepted. ...
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Pr...
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code. “We believe this decision is in the best interests of Sienna and its stakeholders,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “The protections afforded by Chapter 11 provide for ...
Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strat...
Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives to maximize shareholder value. With Cowen's assistance, Sienna will continue to explore capital raising to enable the initiation of its planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib), in...
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare...
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference WESTLAKE VILLAGE, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the BMO Capital Markets Prescriptions for Success Healthcare Conference, Tuesday, June 25, 2019, 1:40 p.m. ET, in New York. The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at . ...
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of...
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology -- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the results of its recent Phase 2b clinical trial with SNA-120 (pegcantratinib), the Company’s Phase 3 topical, non-steroidal Tropomyosin receptor kinase ...
Sienna Biopharmaceuticals to Present at Dermatology Drug Development S...
Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe WESTLAKE VILLAGE, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul, M.D., Ph.D., Chief Medical Officer, and Silvio Traversa, B.Sc., Ph.D., Chief Scientific Officer, are scheduled to present at the Dermatology Drug Development Summit Europe, May 21-23, 2019, in Frankfurt, Germany. Dr. Lizzul also serves as the Summit’s Chair. About the Presentations Title: “Bridging the Innovation Gap in the Treatment of Mild to Moderat...
Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demons...
Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis -- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120 -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase 3 program in second half of 2019 WESTLAKE VILLAGE, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced biopsy data from its recent Phase 2b clinical trial with SNA-1...
Sienna Biopharmaceuticals to Present at BAML Health Care Conference
Sienna Biopharmaceuticals to Present at BAML Health Care Conference WESTLAKE VILLAGE, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care Conference 2019, Wednesday, May 15, 2019, 3:55 p.m. PDT, in Las Vegas. The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at . An archived version of the webcast will be available approximately ...
Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results -- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA) today reported the Company’s financial results for the first quarter of 2019. “We are pleased to report the results of our first quarter,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “We completed a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for SNA-120 (pegca...
Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial O...
Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations -- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the promotion of Alexander Azoy to Chief Financial Officer (CFO). Mr. Azoy, who has served as Sienna’s Corporate Controller since December 2017, will succeed John W. Smither, who has resigned for personal reasons, effective April 1, 2019. “We are...
- Jonathan Moreland
BKD BROOKDALE SENIOR LIVING INC.
WETF WISDOMTREE INVESTMENTS INC.
VRNS VARONIS SYSTEMS INC.
TRVN TREVENA
SBH SALLY BEAUTY HOLDINGS INC.
ONDK ON DECK CAPITAL
NRZ NEW RESIDENTIAL INVESTMENT CORP.
MITT AG MORTGAGE INVESTMENT TRUST INC.
LCI LANNETT COMPANY INC.
HCAP HARVEST CAPITAL CREDIT CORP
GNCA GENOCEA BIOSCIENCES
FOSL FOSSIL GROUP INC.
FFIN FIRST FINANCIAL BANKSHARES INC
EQT EQT CORPORATION
CGIX CANCER GENETICS INC
CALX CALIX NETWORKS
ARMK ARAMARK
ACOR ACORDA THERAPEUTICS INC.
CAI CAI INTERNATIONAL INC.
KMI KINDER MORGAN INC CLASS P
MAT MATTEL INC.
RILY B RILEY SECURITIES INC
X UNITED STATES STEEL CORPORATION
USAP UNIVERSAL STAINLESS & ALLOY PRODUCTS INC.
AGLE AEGLEA BIOTHERAPEUTICS
KEGX KEY ENERGY SVCS
PKTX PROTOKINETIX INC
COT COTT CORPORATION
APRN BLUE APRON HOLDINGS
MLSS MILESTONE SCIENTIFIC
SNNA SIENNA BIOPHARMACEUTICALS INC.
CLF CLIFFS NATURAL RESOURCES INC.
BCBP BCB BANCORP INC.
PWOD PENNS WOODS BANCORP INC.
SFIX STITCH FIX CLASS A
FNCB FIRST NATL COMM BCP
FTLF FITLIFE BRANDS INC
FSK FS KKR CAPITAL CORP
RIVE RIVERVIEW FINANCIAL CORP.
- Jonathan Moreland
BKD BROOKDALE SENIOR LIVING INC.
WETF WISDOMTREE INVESTMENTS INC.
VRNS VARONIS SYSTEMS INC.
TRVN TREVENA
SBH SALLY BEAUTY HOLDINGS INC.
ONDK ON DECK CAPITAL
NRZ NEW RESIDENTIAL INVESTMENT CORP.
MITT AG MORTGAGE INVESTMENT TRUST INC.
LCI LANNETT COMPANY INC.
HCAP HARVEST CAPITAL CREDIT CORP
FOSL FOSSIL GROUP INC.
FFIN FIRST FINANCIAL BANKSHARES INC
EQT EQT CORPORATION
CGIX CANCER GENETICS INC
CALX CALIX NETWORKS
ARMK ARAMARK
ACOR ACORDA THERAPEUTICS INC.
CAI CAI INTERNATIONAL INC.
KMI KINDER MORGAN INC CLASS P
MAT MATTEL INC.
RILY B RILEY SECURITIES INC
X UNITED STATES STEEL CORPORATION
USAP UNIVERSAL STAINLESS & ALLOY PRODUCTS INC.
AGLE AEGLEA BIOTHERAPEUTICS
KEGX KEY ENERGY SVCS
PKTX PROTOKINETIX INC
COT COTT CORPORATION
APRN BLUE APRON HOLDINGS
MLSS MILESTONE SCIENTIFIC
SNNA SIENNA BIOPHARMACEUTICALS INC.
CLF CLIFFS NATURAL RESOURCES INC.
BCBP BCB BANCORP INC.
PWOD PENNS WOODS BANCORP INC.
SFIX STITCH FIX CLASS A
FTLF FITLIFE BRANDS INC
FSK FS KKR CAPITAL CORP
RIVE RIVERVIEW FINANCIAL CORP.
Sienna Biopharmaceuticals to Present at Cowen and Company Health Care ...
Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference WESTLAKE VILLAGE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Cowen and Company 39th Annual Health Care Conference, Monday, Mar. 11, 2019, 11:20 a.m. EDT, in Boston. The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at . An archived vers...
- Jonathan Moreland
ZBH ZIMMER BIOMET HOLDINGS INC.
PE PARSLEY ENERGY INC. CLASS A
BKD BROOKDALE SENIOR LIVING INC.
VRNS VARONIS SYSTEMS INC.
VICL VICAL INC.
TTSH TILE SHOP HOLDINGS INC.
STAG STAG INDUSTRIAL INC.
SFLY SHUTTERFLY INC.
SEAC SEACHANGE INTERNATIONAL INC.
PBPB POTBELLY CORP.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
ONDK ON DECK CAPITAL
OLBK OLD LINE BANCSHARES INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
LAKE LAKELAND INDUSTRIES INC.
IVZ INVESCO LTD.
HSGX HISTOGENICS CORP
GPRO GOPRO INC. CLASS A
GPRE GREEN PLAINS INC.
GNCA GENOCEA BIOSCIENCES
GLPI GAMING AND LEISURE PROPERTIES INC.
FOSL FOSSIL GROUP INC.
FB FACEBOOK INC. CLASS A
ETM ENTERCOM COMMUNICATIONS CORP. CLASS A
EQT EQT CORPORATION
EDIT EDITAS MEDICINE INC.
DVAX DYNAVAX TECHNOLOGIES CORPORATION
CTRL CONTROL4 CORPORATION
CLR CONTINENTAL RESOURCES INC.
CINF CINCINNATI FINANCIAL CORPORATION
ACOR ACORDA THERAPEUTICS INC.
AAT AMERICAN ASSETS TRUST INC.
CBFV CB FINANCIAL SERVICES INC.
CAI CAI INTERNATIONAL INC.
ITI ITERIS
KMI KINDER MORGAN INC CLASS P
MAT MATTEL INC.
NOV. NOV INC.
RILY B RILEY SECURITIES INC
OTEL OTELCO INC
ELF E.L.F. BEAUTY INC.
X UNITED STATES STEEL CORPORATION
USAP UNIVERSAL STAINLESS & ALLOY PRODUCTS INC.
SNAP SNAP INC. CLASS A
KEGX KEY ENERGY SVCS
COT COTT CORPORATION
APRN BLUE APRON HOLDINGS
MLSS MILESTONE SCIENTIFIC
SNNA SIENNA BIOPHARMACEUTICALS INC.
CLF CLIFFS NATURAL RESOURCES INC.
BCBP BCB BANCORP INC.
MPB MID PENN BANCORP INC.
IFMK IFRESH
OPNT OPIANT PHARMACEUTICALS
GULTU GULF COAST ULTRA DEEP ROYALTY TRUST
- Jonathan Moreland
Sienna Biopharmaceuticals Prices Public Offering of Common Stock
Sienna Biopharmaceuticals Prices Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $2.50 per share. The gross proceeds to Sienna from the offering are expected to be $20.0 million, before underwriting discounts and commissions and estimated offering costs. Sienna has granted the underwriters a 30-day option to purchase up to an a...
Sienna Biopharmaceuticals Announces Proposed Public Offering of Common...
Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Sienna. In connection with this offering, Sienna expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered to the public, on ...
Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA...
Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System -- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solutionof silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has potential to expand the $3 billion U.S. laser hair removal market as an effective option for light-haired consumers -- -- Sienna to seek strategic partner for SNA-001, and will continue to focus on Phase 3 development of SNA-120 for Psoriasis and Prurit...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.